Millennium Pharmaceuticals, Inc.

导读近期可谓科学界的收获季，颁发的科学大奖一个接着一个，包括有着科学界“奥斯卡奖”之称的科学突破奖、“诺奖风向标”拉斯克奖等。10月初，诺奖也将拉开帷幕。在这众多奖项中，还有一个奖项值得我们关注，那就是Horwitz奖。Horwitz奖比起拉斯克奖要年轻20来岁，也显得低调不少。然而截止目前，在获得Horwitz奖的科学家113位中，已有51位，也就是超过45%的学者获得了诺奖，它或许是真的“诺奖风向标”。近日，华人学者陈志坚因发现cGAS-STING通路获得2023年Horwitz奖，成为该奖颁奖56年以来的首位华人获奖者。012023 Horwitz奖揭晓，华人学者陈志坚获奖9月20日，2023年Horwitz奖（Horwitz Prize）揭晓，奖项授予了美国德克萨斯大学西南医学中心华人学者陈志坚以及美国迈阿密大学米勒医学院细胞生物学系教授葛兰·巴伯（Glen Barber），以表彰他们在cGAS-STING通路方面的卓越贡献。颁奖典礼和荣誉讲座将于2024年2月12日举行。两位学者的发现，共同揭示了先天免疫系统中一个关键组分，为改变免疫响应以治疗传染病、自身免疫性疾病和癌症等提供了新的途径。当病原体侵入我们的细胞时，它们会在其中留下自己的DNA痕迹。而cGAS-STING通路可以探测到这些“分子指纹”，并发出警报，以激活免疫系统来清除入侵威胁，为开发新的治疗方法奠定了基础，这些方法通过调节免疫反应来应对传染病、自身免疫性疾病、癌症等。02从安溪县走出国门的大科学家1966年，陈志坚出生于中国铁观音之乡——福建安溪县南斗村。早年父亲外出打工，作为小学教师的母亲独自照顾三个孩子的学习和生活，十分不易。陈志坚从小非常懂事，勤于学习，也显现出了出色的学习能力。他以优异的成绩从安溪一中毕业后，考入福建师范大学，攻读生物学，此后以生物化学第一名的成绩拿到海外奖学金，远赴美国纽约州立大学布法罗分校继续攻读生物学，硕博期间他主要研究蛋白质在人体的作用，1991年，陈志坚获得博士学位。接着，他进入索尔克生物研究所继续博士后研究。在完成学业后，陈志坚先是选择进入了工业界，接连在百特医疗保健公司以及马萨诸塞州剑桥市的生物技术公司ProScript担任技术研究员，在ProScript工作期间，他成功开发有助于识别和改进癌症治疗药物Velcade的检测方法，并开始研究泛素。1997年，陈志坚离开工业，重回学界，在德克萨斯大学西南医学中心设立了自己的实验室，继续自己在泛素方面的研究工作。最初，他的研究重心放在泛素在NF-κB蛋白复合物信号通路中的作用，特别是它与免疫反应之间的作用。之后他开始转而研究NF-κB如何启动对流感和丙型肝炎等RNA病毒的免疫反应，在这一过程中，他有了一系列的发现，包括胞质DNA传感器、环GMP-AMP合酶等。2012年，陈志坚有了更大的发现，成功发现cGAS酶，这一发现解决了困扰医学界一个世纪的难题。cGAS能够感知到源自病原体或自身细胞（如自身免疫性疾病或癌症）DNA的存在，并通过释放环二核苷酸小分子来激活免疫系统。同年，他因cGAS酶的发现获得美国国家科学院分子生物学奖；2019年获得科学突破奖；今年，他获得了Horwitz奖。目前，陈志坚教授还是霍华德休斯医学研究所的研究员，2014年当选为美国国家科学院院士。03Louisa Gross Horwitz PrizeHorwitz奖国内可能知道的人不多，但是它大有来头。奖项全称为Louisa Gross Horwitz Prize，是哥伦比亚大学每年颁发的生物、化学领域奖项，主要表彰在基础生物学、生物化学领域中做出突出贡献的科学家。该奖项于1967年设立，创立者为S. Gross Horwitz，以其母亲Louisa Gross Horwitz为奖项命名。迄今为止，已举办56届，共113名科学家获得Horwitz奖，其中51名获奖者已摘得诺奖。近些年，摘得诺奖的是2014年的Horwitz奖获得者James P. Allison与京都大学的本庶佑教授，二人获得了2018年的诺贝尔生理或医学奖。陈志坚和Glen Barber是该奖项的第112位和第113位获奖者。在很多人看来，陈志坚教授的研究发现也属于诺奖级的，未来他或许有望摘得诺奖。参考资料1.Zhijian ‘James’ Chen and Glen Barber Awarded Horwitz Prize for Discovering the cGAS-STING Pathwayhttps://www.cuimc.columbia.edu/news/zhijian-james-chen-and-glen-barber-awarded-horwitz-prize-discovering-cgas-sting-pathway2.https://labs.utsouthwestern.edu/chen-zhijian-james-lab抗体行业在过去几十年中经历了快速而显著的发展，成为生物医药领域中一个快速发展且备受关注的领域。自20世纪80年代第一种单克隆抗体药物（Muromonab-CD3）获得批准以来，许多抗体药物已经被批准用于各种疾病的治疗，包括肿瘤、免疫性疾病和感染性疾病等。市场上已经有数十种成功抗体药物，并且在临床开发和研究中有更多的候选药物，预计未来将有更多新药上市。如今，除了传统的单克隆抗体，越来越多的新型抗体技术被陆续开发出来，包括双特异性抗体、多克隆抗体、人源化抗体、重组抗体、抗体偶联药物等。这些新技术使得抗体药物具有更高的特异性、亲和力、稳定性和生产可行性，拓宽了抗体的应用范围。今年是COVID-19大流行趋于稳定后的第一年，人民生活逐渐走向正轨，经济也在缓慢但有力的复苏之中，而各抗体企业也依然在不断奋进、不断突破、不断超越，使抗体领域蓬勃发展，硕果累累。为促进抗体行业的交流与创新，2023年10月14-15日第六届金秋十月抗体产业发展大会如约而至。会议旨在为研究人员提供一个互动交流的平台，有助于推动抗体产业的进一步发展。会议内容时间：2023年10月14-15日地点：苏州（酒店定向通知）规模：600-800人主办单位：生物制品圈、抗体圈指导单位：康维讯生物、夏尔巴生物会议费用：免费FREE!（仅收取50元报名定金，含参会学习、茶歇、会议手册，定金概不退还），9月15日报名定金提高到100元，先到先得，报完即止，超过9月20日预登记将收取会议费！报名方式：扫描下方二维码或点击文章最底部“阅读原文”→ 填写表格 → 报名成功（报名志愿者，承担一定工作，请慎重考虑，免交定金）！组委会获得报名信息后，根据报名信息进行初筛，并进一步与报名者沟通确认，实现精准邀请。最终有机会进入大会微信群（严格审核通过）。日程安排更多嘉宾仍在邀请中。。。。。。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

Jeet Mahal Continues as COOREDWOOD CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimens, today announced the appointment of Herb Cross, an experienced senior financial executive, as the company’s Chief Financial Officer (CFO). Jeet Mahal, who previously held both CFO and Chief Operating Officer (COO) roles, will continue as the company’s COO. “We are very pleased to welcome Herb, who brings more than twenty years of public company executive leadership experience to our team, as our new CFO,” said Ronald Martell, Chief Executive Officer of Jasper. “With multiple clinical studies of briquilimab in Chronic Spontaneous Urticaria, Low to Intermediate Risk MDS and hematopoietic stem cell transplant either ongoing or planned to start this year, we are taking the opportunity to strengthen our leadership team in preparation for continued growth. The addition of Herb also allows Jeet Mahal to focus on our increasing operational needs in his ongoing role as our COO.” "I am excited to join Jasper at an important time in its development, particularly given the growing set of compelling data supporting the continued development of briquilimab,” said Herb Cross. “I look forward to building on the company’s strong foundation and am eager to begin working with the leadership team to help realize briquilimab’s potential.” Mr. Cross brings more than two decades of experience in financial leadership roles at both public and private biotechnology companies. Before joining Jasper, he served as CFO at Atreca, leading its initial public offering and holding responsibility for all administrative functions, including finance, corporate communications, human resources and corporate services. Prior to Atreca, he was CFO at ARMO BioSciences, with responsibility for all administrative functions and business development, and led its initial public offering and served as CFO through the sale of the company to Eli Lilly in 2018. Mr. Cross also served as CFO and interim Chief Executive Officer at KaloBios Pharmaceuticals and was CFO at Affymax as well. Mr. Cross began his career at Arthur Andersen, LLP, and received a Bachelor of Science in Business Administration from the Haas School of Business at the University of California, Berkeley. He is a certified public accountant, currently inactive, in the state of California. Mr. Mahal joined Jasper in December 2019 from Portola Pharmaceuticals, where he worked for 11 years and held a number of positions of increasing leadership, most recently as Vice President, Business Development and Vice President, Strategic Marketing. He led the successful execution of multiple business development partnerships for Andexxa®, Bevyxxa® and cerdulatinib. He also played a key role in Portola Pharmaceuticals’ equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, he was Director, Business and New Product Development, at Johnson & Johnson on the Xarelto® development and strategic marketing team. He started his career in the drug development laboratories at COR Therapeutics. Inducement Grant In connection with the appointment of Mr. Cross as its Chief Financial Officer, on September 22, 2023, Jasper granted Mr. Cross an option to purchase 550,000 shares of its voting common stock (the “Option”). The Option was granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, as approved by the compensation committee of Jasper’s board of directors on March 14, 2022 and as amended and restated on June 2, 2023, and was granted as an inducement material to Mr. Cross’ employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of the Option is $0.78. The Option will vest over four years, with 25% of the total number of shares vesting on September 22, 2024 and 1/48th of the total number of shares subject to the Option vesting monthly thereafter, subject in each case to Mr. Cross’ continued service to Jasper on each vesting date. Jasper is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Jasper Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 145 dosed patients and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. For more information, please visit us at www.jaspertherapeutics.com. Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, the development of briquilimab for CSU, LR-MDS and stem cell transplant conditioning and plans to commence multiple clinical studies of briquilimab, briquilimab’s further development and the strategic direction for briquilimab. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: John Mullaly (investors)LifeSci Advisors617-429-3548jmullaly@lifesciadvisors.com Jeet Mahal (investors)Jasper Therapeutics650-549-1403jmahal@jaspertherapeutics.com Lauren Barbiero (media)Real Chemistry646-564-2156lbarbiero@realchemistry.com

SINGAPORE, Sept. 25, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA). "We're thrilled to strengthen our existing suite of patents," said Peter Choo, Chairman of CytoMed. "Now this novel iPSC-based technology has been granted patent in China and Japan (where the iPSC technology was pioneered in 2006). Such progress further expands the Company's current patent portfolio to three countries, consisting of and including patents granted in the US and China for our licensed allogeneic chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology which is expected to start phase I clinical trial in Singapore soon." For cancer treatment, immune cells such as γδ T cells and natural killer (NK) cells are invaluable therapeutic cells due to their ability to express an array of built-in receptors that recognize stress-induced cancer antigens naturally. By combining the iPSC technology and directed differentiation, CytoMed can generate a novel type of synthetic hybrid immune cells, γδ NKT cells, that express cancer recognition receptors of both γδ T cells and NK cells to recognize a wide range of cancers without genetic modification or use of viral vectors. As an allogeneic cell source, the Company's iPSC-derived γδ NKT cells may potentially become an "off-the-shelf" cell therapy that is applicable to a large pool of patients. The patent titled "Methods and Kits for Generating Mimetic Innate Immune Cells from Pluripotent Stem Cells" with Patent No. ZL201880022790.X, published as CN 110691844 B, covers technologies to derive novel synthetic γδ NKT cells for the treatment of various types of cancers including hematological malignancies and solid tumors. This asset is currently under preclinical development. The Company holds an exclusive, worldwide license to use this patent pursuant to the Licence Agreement dated June 1, 2018, which was filed with the Securities and Exchange Commission as an exhibit to the registration statement on Form F-1 (File No.: 333-268456) on March 30, 2023. About CytoMed Therapeutics Limited (CytoMed) Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development agency in the public sector. It is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating hematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. For more information, please visit and follow us on Twitter @CytomedSG,on LinkedIn, and Facebook Forward Look Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical trials and the Company's R&D programs; the Company's expectations regarding the impact of the ongoing COVID-19 pandemic on its business, the Company's industry and the economy; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at . The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof. SOURCE CytoMed Therapeutics Limited